Mythic Therapeutics Presents Promising Preclinical Results for MYTX-011 Targeting Diverse Tumor Mutations at AACR 2025
Mythic Therapeutics Presents Promising Preclinical Data Demonstrating Broad Antitumor Efficacy of MYTX-011 at the 2025 AACR Annual Meeting Mythic Therapeutics, a clinical-stage biotechnology company pioneering the next generation of antibody-drug conjugates (ADCs), today unveiled compelling preclinical data supporting the broad…
Devonian Health Group Announces Resumption of Trading on TSXV
Devonian Health Group Inc. Announces Reinstatement of Trading on TSX Venture Exchange Following Resolution of Cease Trade Order Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a late-stage botanical pharmaceutical corporation, today announced a significant corporate…
Puma Biotechnology Showcases Neratinib Clinical Findings at AACR Annual Meeting 2025
Puma Biotechnology Showcases Promising Neratinib Combination Data at AACR Annual Meeting 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company specializing in the development of innovative cancer treatments, has presented new clinical data on its lead drug candidate, neratinib (NERLYNX®),…
Agenus Unveils Promising BOT/BAL Neoadjuvant Pan-Cancer Findings from NEOASIS Study at AACR
Agenus Presents Promising BOT/BAL Neoadjuvant Pan-Cancer Data from NEOASIS Study at AACR Annual Meeting Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing therapies designed to activate the body’s immune system to fight cancer, announced the presentation of…
LEAP Drives Growth in Digital Lab Transformation with New Clinical Diagnostics Executive
LEAP Consulting Group Accelerates Clinical Lab Digital Transformation with Appointment of Dr. Heather E. Williams as Practice Principal, Life Sciences LEAP Consulting Group, a boutique digital consultancy recognized for its domain expertise in the clinical diagnostics space, has announced a…
Fellow Health to Unveil Cutting-Edge Prostate Cancer and PVSA Findings at AUA 2025
Fellow Health to Present Groundbreaking Research on Prostate Cancer Biomarkers and Mail-In PVSA Testing at AUA 2025 Fellow Health, a pioneering healthcare company dedicated to advancing male reproductive health through innovative, patient-centered diagnostics, today announced that it will present four…
Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development
Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development, Signaling Strategic Growth in Clinical Pipeline Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company advancing novel treatments for serious central nervous system (CNS) and immunologic…
Medifast Releases First Quarter 2025 Earnings
Medifast Reports First Quarter 2025 Financial Results, Focuses on Revitalizing Growth and Enhancing Wellness Offerings Medifast, a leading health and wellness company known for its clinically supported and coach-guided lifestyle solution, OPTAVIA®, has announced its financial results for the first…
Dyno Therapeutics to Unveil Pioneering AAV Gene Delivery Data Targeting CNS, Eye, and Muscle at ASGCT 28th Annual Meeting
Dyno Therapeutics to Present Cutting-Edge AAV Gene Delivery Data for CNS, Eye, and Muscle at 2025 ASGCT Annual Meeting Dyno Therapeutics, Inc., a pioneer in genetic technologies harnessing the power of artificial intelligence (AI) to revolutionize in vivo gene delivery,…
Obsidian Therapeutics to Showcase Preclinical Data on cytoDRiVE® Platform at ASGCT Annual Meeting
Obsidian Therapeutics to Present Groundbreaking Preclinical Data on cytoDRiVE® Platform at the 2025 ASGCT Annual Meeting Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to cell and gene therapy through synthetic biology, has announced the acceptance of a…
Sangamo Therapeutics to Showcase Neurology Pipeline Progress at 28th Annual ASGCT Meeting
Sangamo Therapeutics to Highlight Neurology Pipeline Innovations with Nine Presentations at 28th ASGCT Annual Meeting Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company focused on developing transformative therapies for serious neurological conditions, announced that nine of its scientific abstracts…
Capsida to Share STXBP1-DEE Program Updates at ASGCT Meeting
Capsida Biotherapeutics to Present Broad Pipeline and Platform Advances at ASGCT 2025 Annual Meeting Capsida Biotherapeutics (“Capsida”), a biotechnology company focused on developing targeted gene therapies for serious neurological and systemic disorders, announced today that it will present significant new…